Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Moxetumomab pasudotox - AstraZeneca

Next Previous
Drug Profile

Moxetumomab pasudotox - AstraZeneca

Alternative Names: CAT-8015; CD22-directed immunotoxin; GCR-8015; HA22; LUMOXITI; Lumoxiti; Moxetumomab pasudotox-tdfk

Latest Information Update: 04 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer AstraZeneca; M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Peptide elongation factor 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hairy cell leukaemia
  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 04 Apr 2024 AstraZeneca terminates its licence for moxetumomab pasudotox to Innate Pharma in USA, European Union and Switzerland
  • 08 Feb 2021 Registered for Hairy cell leukaemia (Second-line therapy or greater) in European Union, Norway, Liechtenstein, Iceland (IV)
  • 01 Jan 2021 The CHMP recommends approval of moxetumomab pasudotox for hairy cell leukaemia (Late-stage disease, Second-line therapy or greater) in the EU

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top